Glecaprevir / Pibrentasvir Oral Tablet [Mavyret] — Competitive Intelligence Brief

Glecaprevir / Pibrentasvir Oral Tablet [Mavyret] (Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct-acting antiviral (DAA) combination. Area: Virology / Hepatology.

marketed Direct-acting antiviral (DAA) combination HCV NS3/4A protease and NS5A protein Virology / Hepatology Small molecule

Target snapshot

Glecaprevir / Pibrentasvir Oral Tablet [Mavyret] (Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]) — Massachusetts General Hospital. Glecaprevir and pibrentasvir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS3/4A protease and NS5A protein, respectively, blocking viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Glecaprevir / Pibrentasvir Oral Tablet [Mavyret] TARGET	Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
glecaprevir/pibrentasvir tablets	glecaprevir/pibrentasvir tablets	Raymond T. Chung, MD	marketed	Direct-acting antiviral combination (NS3/4A protease inhibitor + NS5A inhibitor)	HCV NS3/4A protease and NS5A protein
Post-transplant Grazoprevir and Elbasvir	Post-transplant Grazoprevir and Elbasvir	University of Maryland, Baltimore	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
Grazaoprevir/Elbasavir	Grazaoprevir/Elbasavir	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
Glecaprevir and Pibrentasvir	Glecaprevir and Pibrentasvir	Massachusetts General Hospital	marketed	Direct-acting antiviral combination (NS3/4A protease inhibitor + NS5A inhibitor)	HCV NS3/4A protease and NS5A protein
Grazoprevir/Elbasvir	Grazoprevir/Elbasvir	Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
MK5172 /MK8742	MK5172 /MK8742	Istituto Clinico Humanitas	phase 3	Direct-acting antiviral combination (NS3/4A protease inhibitor + NS5A inhibitor)	HCV NS3/4A protease and NS5A protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct-acting antiviral (DAA) combination class)

1. Massachusetts General Hospital · 3 drugs in this class
2. Egyptian Liver Hospital · 3 drugs in this class
3. Hannover Medical School · 2 drugs in this class
4. University of Maryland, Baltimore · 2 drugs in this class
5. Iran Hepatitis Network · 2 drugs in this class
6. Partners in Health · 2 drugs in this class
7. HaEmek Medical Center, Israel · 1 drug in this class
8. Almaza Military Fever Hospital · 1 drug in this class
9. Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba · 1 drug in this class
10. Federal University of São Paulo · 1 drug in this class